What is GRAIL?
GRAIL operates at the intersection of genomics and data science, focusing on the development of innovative technologies designed to detect cancer at its earliest, most treatable stages. By analyzing circulating cell-free DNA in the bloodstream, the company provides healthcare providers and oncologists with actionable insights that aim to fundamentally shift the trajectory of cancer mortality. Its market position is defined by a commitment to high-throughput diagnostic precision, positioning it as a leader in the burgeoning field of liquid biopsy and proactive health screening solutions.
How much funding has GRAIL raised?
GRAIL has raised a total of $2.3B across 7 funding rounds:
Series A
$100M
Series B
$900M
Series C
$300M
Unspecified
$125M
Series D
$390M
Stock/Share Issuance
$325M
Stock/Share Issuance
$110M
Series A (2016): $100M with participation from Bezos Expeditions, ILLUMINA, GV, Sutter Hill Ventures, Biomatics Capital, ARCH Venture Partners, Bill Gates, and Longwood Fund
Series B (2017): $900M led by Celgene, McKesson, ARCH Venture Partners, Amazon, Bristol-Myers Squibb, Varian Medical Systems, Tencent HOldings Limited, Merck, and JJDC
Series C (2018): $300M supported by ICBC International, China Merchants Securities, WuXi NextCODE, Ally Bridge Group, HuangPu River Capital, CRF Investment, Hillhouse Capital Group, Sequoia Capital China, Dimensions Capital, and Blue Pool Capital
Unspecified (2019): $125M, investors not publicly disclosed
Series D (2020): $390M backed by Illumina, Inc., CPP Investments, and Public Sector Pension Investment Board
Stock/Share Issuance (2025): $325M with participation from Deep Track Capital, Farallon, Braidwell, and Him & Her
Stock/Share Issuance (2026): $110M led by Samsung C&T
Key Investors in GRAIL
ARCH Venture Partners
A leading early-stage venture capital firm that specializes in co-founding and scaling life sciences and advanced technology companies by commercializing innovations from research institutions.
ILLUMINA
A global leader in sequencing and array-based solutions for genetic and genomic analysis, providing the foundational technology that powers GRAIL's diagnostic capabilities.
Amazon
A global technology conglomerate with a strategic interest in healthcare innovation, cloud computing, and data-driven solutions that can scale complex diagnostic platforms.
What's next for GRAIL?
With this major enterprise-level funding, GRAIL is well-positioned to deepen its clinical research and broaden the adoption of its multi-cancer early detection platform. The strategic roadmap likely involves scaling manufacturing capabilities for the Galleri test, expanding partnerships with global healthcare systems, and refining its machine-learning algorithms to enhance diagnostic sensitivity. As the company matures, the focus will shift toward integrating these detection technologies into standard clinical workflows, ultimately aiming to establish a new global benchmark for cancer screening and patient outcomes.
See full GRAIL company page
